Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials WSME Theelen, D Chen, V Verma, BP Hobbs, HMU Peulen, JGJV Aerts, ... The Lancet Respiratory Medicine 9 (5), 467-475, 2021 | 344 | 2021 |
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors V Verma, T Sprave, W Haque, CB Simone, JY Chang, JW Welsh, ... Journal for immunotherapy of cancer 6, 1-15, 2018 | 276 | 2018 |
Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy W Haque, V Verma, S Hatch, V Suzanne Klimberg, E Brian Butler, BS Teh Breast cancer research and treatment 170, 559-567, 2018 | 266 | 2018 |
A systematic review of the cost and cost‐effectiveness studies of proton radiotherapy V Verma, MV Mishra, MP Mehta Cancer 122 (10), 1483-1501, 2016 | 220 | 2016 |
Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer SH Lin, BP Hobbs, V Verma, RS Tidwell, GL Smith, X Lei, EM Corsini, ... Journal of Clinical Oncology 38 (14), 1569, 2020 | 202 | 2020 |
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified … JY Chang, RJ Mehran, L Feng, V Verma, Z Liao, JW Welsh, SH Lin, ... The Lancet Oncology 22 (10), 1448-1457, 2021 | 196 | 2021 |
Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy T Sprave, V Verma, R Förster, I Schlampp, T Bruckner, T Bostel, SE Welte, ... Radiotherapy and Oncology 128 (2), 274-282, 2018 | 194 | 2018 |
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial J Welsh, H Menon, D Chen, V Verma, C Tang, M Altan, K Hess, ... Journal for immunotherapy of cancer 8 (2), 2020 | 174 | 2020 |
Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases: the FIRE-SCLC cohort study CG Rusthoven, M Yamamoto, D Bernhardt, DE Smith, D Gao, T Serizawa, ... JAMA oncology 6 (7), 1028-1037, 2020 | 152 | 2020 |
Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non–small cell lung cancer: final results of a phase 2 study JY Chang, V Verma, M Li, W Zhang, R Komaki, C Lu, PK Allen, Z Liao, ... JAMA oncology 3 (8), e172032-e172032, 2017 | 141 | 2017 |
A systematic review and meta-analysis of cancer patients affected by a novel coronavirus BP Venkatesulu, VT Chandrasekar, P Girdhar, P Advani, A Sharma, ... JNCI cancer spectrum 5 (2), pkaa102, 2021 | 137 | 2021 |
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort M Stahl, M DeVeaux, P Montesinos, R Itzykson, EK Ritchie, MA Sekeres, ... Blood advances 2 (8), 923-932, 2018 | 132 | 2018 |
Role of radiation therapy in modulation of the tumor stroma and microenvironment H Menon, R Ramapriyan, TR Cushman, V Verma, HH Kim, C Atalar, ... Frontiers in immunology 10, 432757, 2019 | 131 | 2019 |
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer XS Wang, YF Bai, V Verma, RL Yu, W Tian, R Ao, Y Deng, XQ Zhu, H Liu, ... JNCI: Journal of the National Cancer Institute 115 (6), 742-748, 2023 | 127 | 2023 |
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort M Stahl, M DeVeaux, T De Witte, J Neukirchen, MA Sekeres, AM Brunner, ... Blood advances 2 (14), 1765-1772, 2018 | 120 | 2018 |
Radiotherapy workflow and protection procedures during the Coronavirus Disease 2019 (COVID-19) outbreak: Experience of the Hubei Cancer Hospital in Wuhan, China W Wei, D Zheng, Y Lei, S Wu, V Verma, Y Liu, X Wei, J Bi, D Hu, G Han Radiotherapy and Oncology 148, 203-210, 2020 | 118 | 2020 |
The rise of radiomics and implications for oncologic management V Verma, CB Simone, S Krishnan, SH Lin, J Yang, SM Hahn JNCI: Journal of the National Cancer Institute 109 (7), djx055, 2017 | 118 | 2017 |
Quality of life and patient-reported outcomes following proton radiation therapy: a systematic review V Verma, CB Simone, MV Mishra JNCI: Journal of the National Cancer Institute 110 (4), 341-353, 2018 | 107 | 2018 |
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy H Menon, D Chen, R Ramapriyan, V Verma, HB Barsoumian, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 105 | 2019 |
Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation–related abscopal responses JW Welsh, C Tang, P De Groot, A Naing, KR Hess, JV Heymach, ... Cancer immunology research 7 (12), 1903-1909, 2019 | 98 | 2019 |